Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Files for IPO in Europe

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia has filed for an initial public offering to sell shares on the NYSE Euronext in Amsterdam.

The Dutch molecular diagnostics firm plans to sell up to 4,587,156 newly issued ordinary shares at a price of between €16.35 to €19.15 per share. At the mid-point of that range, it would raise around €81.4 million ($119 million), before an over-allotment option of up to 688,073 newly issued ordinary shares.

Agendia expects to begin trading on the NYSE Euronext in Amsterdam on June 21, under the symbol "AGDX".

The firm will use the proceeds partly to expand its sales and marketing efforts in the US. Agendia sells the MammaPrint breast cancer recurrence assay, the first in vitro diagnostic multivariate index assay device approved by the US Food and Drug Administration in early 2007.

The Scan

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.